Fresenius SE & Co KGaA (FRA:FRE) has been given a €47.00 ($55.29) price objective by equities researchers at Goldman Sachs Group in a research note issued to investors on Wednesday, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the stock. Goldman Sachs Group’s price objective suggests a potential upside of 23.81% from the stock’s current price.
A number of other equities research analysts also recently issued reports on the stock. Nord/LB set a €40.00 ($47.06) target price on shares of Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Deutsche Bank set a €57.00 ($67.06) price target on Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Friday, July 31st. Independent Research set a €52.00 ($61.18) price objective on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Friday, July 31st. Jefferies Financial Group set a €35.00 ($41.18) target price on Fresenius SE & Co KGaA and gave the company a “sell” rating in a report on Wednesday, August 5th. Finally, Sanford C. Bernstein set a €47.00 ($55.29) price target on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research note on Thursday, July 30th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eleven have issued a buy rating to the company. Fresenius SE & Co KGaA has a consensus rating of “Buy” and an average price target of €51.46 ($60.54).
Shares of FRA FRE opened at €37.96 ($44.66) on Wednesday. Fresenius SE & Co KGaA has a 52-week low of €60.16 ($70.78) and a 52-week high of €80.00 ($94.12). The stock’s fifty day simple moving average is €39.17 and its 200 day simple moving average is €40.05.
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Recommended Story: What is the CAC 40 Index?
Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.